MA55025A - Anticorps anti-trem2 et leurs procédés d'utilisation - Google Patents
Anticorps anti-trem2 et leurs procédés d'utilisationInfo
- Publication number
- MA55025A MA55025A MA055025A MA55025A MA55025A MA 55025 A MA55025 A MA 55025A MA 055025 A MA055025 A MA 055025A MA 55025 A MA55025 A MA 55025A MA 55025 A MA55025 A MA 55025A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55025A true MA55025A (fr) | 2021-12-29 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055025A MA55025A (fr) | 2019-02-20 | 2020-02-20 | Anticorps anti-trem2 et leurs procédés d'utilisation |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220073609A1 (fr) |
| EP (1) | EP3927743A1 (fr) |
| JP (2) | JP7543290B2 (fr) |
| KR (1) | KR20210135518A (fr) |
| CN (1) | CN113614110B (fr) |
| AR (1) | AR118144A1 (fr) |
| AU (1) | AU2020226754A1 (fr) |
| BR (1) | BR112021015656A2 (fr) |
| CA (1) | CA3130086A1 (fr) |
| CL (1) | CL2021002206A1 (fr) |
| CO (1) | CO2021012230A2 (fr) |
| EA (1) | EA202192294A1 (fr) |
| EC (1) | ECSP21069105A (fr) |
| IL (1) | IL285651A (fr) |
| MA (1) | MA55025A (fr) |
| MX (1) | MX2021009722A (fr) |
| PE (1) | PE20211979A1 (fr) |
| PH (1) | PH12021552002A1 (fr) |
| SG (1) | SG11202108734VA (fr) |
| TW (1) | TWI879756B (fr) |
| WO (2) | WO2020172457A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| AU2019404098A1 (en) * | 2018-12-18 | 2021-05-27 | Boehringer Ingelheim Io Canada Inc. | FLT3 agonist antibodies and uses thereof |
| CN113614110B (zh) | 2019-02-20 | 2025-03-25 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
| AU2021208482B2 (en) * | 2020-01-13 | 2025-12-11 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| KR20230093010A (ko) * | 2020-10-21 | 2023-06-26 | 이뮨-온크 테라퓨틱스, 인코포레이티드 | 신규 항-lilrb2 항체 및 유도체 생성물 |
| JP2024518545A (ja) * | 2021-05-14 | 2024-05-01 | ジェネンテック， インコーポレイテッド | Ｔｒｅｍ２のアゴニスト |
| CN118765204A (zh) | 2022-02-23 | 2024-10-11 | 艾利妥 | 抗trem2抗体的使用方法 |
| US20250215077A1 (en) | 2022-03-28 | 2025-07-03 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (fr) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Méthodes de traitement de l'hypométabolisme du glucose cérébral |
| CN120603851A (zh) | 2023-01-30 | 2025-09-05 | 伊萨尔生物科学有限责任公司 | 用于治疗神经退行性疾病的人抗trem2抗体 |
| CN121666400A (zh) | 2023-08-09 | 2026-03-13 | 豪夫迈·罗氏有限公司 | 单特异性和多特异性抗trem2抗体、其方法和用途 |
| WO2025032069A1 (fr) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Anticorps anti-trem2 mono et multispécifiques, procédés et utilisations associés |
| US20250101101A1 (en) | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025106361A1 (fr) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Agents de liaison à la nectine-4 humaine |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US20120016112A1 (en) | 2009-01-06 | 2012-01-19 | Nestec S.A. | Processing of macronutrients |
| SG173705A1 (en) | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| AU2012274461A1 (en) * | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| FI3677591T3 (fi) | 2013-04-29 | 2023-04-03 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b |
| CA2922979A1 (fr) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Molecules de liaison bispecifiques facilement isolees au format natif, mais possedant des regions constantes mutees |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| EA201790342A1 (ru) * | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| IL283834B (en) | 2014-09-28 | 2022-07-01 | Univ California | Modulation of stimulatory and non-stimulatory myeloid cells |
| EP3973980A1 (fr) * | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
| WO2017058866A1 (fr) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anticorps anti-trem2 et leurs utilisations |
| SG10201912150TA (en) * | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| EP3448874A4 (fr) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| CA3030785A1 (fr) | 2016-07-22 | 2018-01-25 | Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) | Modulateurs du clivage de trem2 et leurs utilisations |
| EP3559043A4 (fr) | 2016-12-23 | 2020-08-05 | Bluefin Biomedicine, Inc. | Anticorps anti-sez6l2 et conjugués anticorps-médicaments |
| US20190367623A1 (en) | 2017-01-17 | 2019-12-05 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| ES2932759T3 (es) | 2017-02-17 | 2023-01-25 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| MD3601358T2 (ro) | 2017-08-03 | 2023-10-31 | Alector Llc | Anticorpi anti-TREM2 și metode de utilizare a acestora |
| EP3665194A4 (fr) | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | Procédés basés sur l'affinité pour utiliser des protéines de liaison au récepteur de transferrine |
| JP7403441B2 (ja) | 2017-09-14 | 2023-12-22 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (fr) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anticorps anti-bace1 et leurs procédés d'utilisation |
| CA3083660A1 (fr) | 2017-12-12 | 2019-06-20 | Pionyr Immunotherapeutics, Inc. | Anticorps anti-trem2 et methodes associees |
| WO2019140050A1 (fr) | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Polypeptides de liaison au récepteur de la transferrine et utilisations associées |
| US20210284702A1 (en) | 2018-06-18 | 2021-09-16 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| CN112839955A (zh) | 2018-08-16 | 2021-05-25 | 戴纳立制药公司 | 经工程改造双特异性蛋白 |
| TW202017947A (zh) | 2018-08-22 | 2020-05-16 | 美商戴納立製藥公司 | 抗her2 多肽及其使用方法 |
| BR112021004316A2 (pt) | 2018-09-11 | 2021-11-03 | Washington University St Louis | Anticorpos de agonistas anti-trem-2 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
| EP3898691A4 (fr) | 2018-12-10 | 2022-09-14 | Mor Research Applications | Anticorps trem2 et leurs utilisations |
| MA54450A (fr) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc | Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation |
| EP3893931A4 (fr) | 2018-12-11 | 2022-09-07 | Pionyr Immunotherapeutics, Inc. | Méthodes d'utilisation d'anticorps anti-trem2 |
| CN113614110B (zh) | 2019-02-20 | 2025-03-25 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
| WO2020194317A1 (fr) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Méthode de traitement de troubles liés aux lipides |
| KR20220004651A (ko) | 2019-04-03 | 2022-01-11 | 데날리 테라퓨틱스 인크. | 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제 |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| AU2021208482B2 (en) | 2020-01-13 | 2025-12-11 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021146256A1 (fr) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
| EP4100419A4 (fr) | 2020-02-07 | 2024-05-29 | Denali Therapeutics Inc. | Procédés de traitement de la maladie de hunter |
| BR112022016232A2 (pt) | 2020-02-19 | 2022-11-16 | Denali Therapeutics Inc | Proteínas biespecíficas anti-her2 manipuladas |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
-
2020
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 CA CA3130086A patent/CA3130086A1/fr active Pending
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/fr not_active Ceased
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/fr active Pending
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/fr not_active Ceased
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko not_active Ceased
-
2021
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP2024164116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192294A1 (ru) | 2021-12-24 |
| EP3927743A1 (fr) | 2021-12-29 |
| JP2024164116A (ja) | 2024-11-26 |
| IL285651A (en) | 2021-09-30 |
| US20220119522A1 (en) | 2022-04-21 |
| TW202045543A (zh) | 2020-12-16 |
| AU2020226754A1 (en) | 2021-09-16 |
| TWI879756B (zh) | 2025-04-11 |
| CO2021012230A2 (es) | 2021-09-30 |
| MX2021009722A (es) | 2021-09-14 |
| CN113614110A (zh) | 2021-11-05 |
| PH12021552002A1 (en) | 2022-09-19 |
| AR118144A1 (es) | 2021-09-22 |
| JP2022520868A (ja) | 2022-04-01 |
| US20220073609A1 (en) | 2022-03-10 |
| KR20210135518A (ko) | 2021-11-15 |
| ECSP21069105A (es) | 2021-11-18 |
| US12240902B2 (en) | 2025-03-04 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| CN113614110B (zh) | 2025-03-25 |
| JP7543290B2 (ja) | 2024-09-02 |
| WO2020172450A1 (fr) | 2020-08-27 |
| SG11202108734VA (en) | 2021-09-29 |
| WO2020172457A1 (fr) | 2020-08-27 |
| CA3130086A1 (fr) | 2020-08-27 |
| PE20211979A1 (es) | 2021-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
| MA56074A (fr) | Anticorps contre le sars-cov-2 et leurs procédés d'utilisation | |
| MA52390A (fr) | Anticorps anti-coronavirus et procédés d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| EP3797123A4 (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| EP3826641A4 (fr) | Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation | |
| EP3917564A4 (fr) | Anticorps anti-claudine 18 et leurs méthodes d'utilisation | |
| EP3852805A4 (fr) | Anticorps anti-lilrb2 et leurs méthodes d'utilisation | |
| EP3953385A4 (fr) | Anticorps cd19 et leurs procédés d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| EP3731867A4 (fr) | Anticorps anti-lrp5/6 et leurs procédés d'utilisation | |
| MA53328A (fr) | Anticorps anti-siglec-5 et leurs procédés d'utilisation | |
| EP3472200A4 (fr) | Anticorps anti-myostatine et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| EP3436476A4 (fr) | Anticorps anti-ryk et leurs procédés d'utilisation | |
| EP3873939A4 (fr) | Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation | |
| EP3938400A4 (fr) | Anticorps cd22 et leurs procédés d'utilisation | |
| EP3710589A4 (fr) | Anticorps anti-c1s et procédés d'utilisation | |
| EP3966248A4 (fr) | Anticorps humanisés dirigés contre la mucine-16 et leurs procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| MA51207A (fr) | Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation | |
| EP3873941A4 (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés | |
| EP3880714A4 (fr) | Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation |